Haemostatic management of intraoral bleeding in patients with congenital deficiency of α2-plasmin inhibitor or plasminogen activator inhibitor-1
Summary. Haemostatic management of intraoral bleeding was investigated in patients with congenital α2-plasmin inhibitor (α2-PI) deficiency or congenital plasminogen activator inhibitor- 1 (PAI-1) deficiency. When extracting teeth from patients with congenital α2-PI deficiency, we advocate that 7.5–...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Morimoto, Y. [verfasserIn] Yoshioka, A. [verfasserIn] Imai, Y. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Oxford, UK: Blackwell Science Ltd ; 2004 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2004 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: Haemophilia - Oxford [u.a.] : Wiley-Blackwell, 1995, 10(2004), 5, Seite 0 |
| Übergeordnetes Werk: |
volume:10 ; year:2004 ; number:5 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1111/j.1365-2516.2004.00914.x |
|---|
| Katalog-ID: |
NLEJ242800688 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ242800688 | ||
| 003 | DE-627 | ||
| 005 | 20210707164245.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s2004 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/j.1365-2516.2004.00914.x |2 doi | |
| 035 | |a (DE-627)NLEJ242800688 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a Morimoto, Y. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Haemostatic management of intraoral bleeding in patients with congenital deficiency of α2-plasmin inhibitor or plasminogen activator inhibitor-1 |
| 264 | 1 | |a Oxford, UK |b Blackwell Science Ltd |c 2004 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Summary. Haemostatic management of intraoral bleeding was investigated in patients with congenital α2-plasmin inhibitor (α2-PI) deficiency or congenital plasminogen activator inhibitor- 1 (PAI-1) deficiency. When extracting teeth from patients with congenital α2-PI deficiency, we advocate that 7.5–10 mg kg−1 of tranexamic acid be administered orally every 6 h, starting 3 h before surgery and continuing for about 7 days. For the treatment of continuous bleeding, such as post-extraction bleeding, 20 mg kg−1 of tranexamic acid should be administered intravenously, and after achieving local haemostasis 7.5 mg kg−1 of tranexamic acid should be administered orally every 6 h for several days. In addition, when treating haematoma caused by labial or gingival laceration or buccal or mandibular contusion, haemostasis should be achieved by administering 7.5–10 mg kg−1 of tranexamic acid every 6 h. Tranexamic acid can also be used for haemostatic management of intraoral bleeding in patients with congenital PAI-1 deficiency, but is less effective when compared with use in patients with congenital α2-PI deficiency. Continuous infusion of 1.5 mg kg−1 h−1 of tranexamic acid is necessary for impacted tooth extraction requiring gingival incision or removal of local bone. | ||
| 533 | |d 2004 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2004|||||||||| | ||
| 650 | 4 | |a congenital α2-plasmin inhibitor deficiency | |
| 700 | 1 | |a Yoshioka, A. |e verfasserin |4 aut | |
| 700 | 1 | |a Imai, Y. |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Y. |4 oth | |
| 700 | 1 | |a Minowa, H. |4 oth | |
| 700 | 1 | |a Kirita, T. |4 oth | |
| 773 | 0 | 8 | |i In |t Haemophilia |d Oxford [u.a.] : Wiley-Blackwell, 1995 |g 10(2004), 5, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243925867 |w (DE-600)2006344-1 |x 1365-2516 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2004 |g number:5 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1365-2516.2004.00914.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2004 |e 5 |h 0 | ||
| author_variant |
y m ym a y ay y i yi |
|---|---|
| matchkey_str |
article:13652516:2004----::amsaimngmnoitarlleignainsihogntleiinyfpamnniio |
| hierarchy_sort_str |
2004 |
| publishDate |
2004 |
| allfields |
10.1111/j.1365-2516.2004.00914.x doi (DE-627)NLEJ242800688 DE-627 ger DE-627 rakwb Morimoto, Y. verfasserin aut Haemostatic management of intraoral bleeding in patients with congenital deficiency of α2-plasmin inhibitor or plasminogen activator inhibitor-1 Oxford, UK Blackwell Science Ltd 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary. Haemostatic management of intraoral bleeding was investigated in patients with congenital α2-plasmin inhibitor (α2-PI) deficiency or congenital plasminogen activator inhibitor- 1 (PAI-1) deficiency. When extracting teeth from patients with congenital α2-PI deficiency, we advocate that 7.5–10 mg kg−1 of tranexamic acid be administered orally every 6 h, starting 3 h before surgery and continuing for about 7 days. For the treatment of continuous bleeding, such as post-extraction bleeding, 20 mg kg−1 of tranexamic acid should be administered intravenously, and after achieving local haemostasis 7.5 mg kg−1 of tranexamic acid should be administered orally every 6 h for several days. In addition, when treating haematoma caused by labial or gingival laceration or buccal or mandibular contusion, haemostasis should be achieved by administering 7.5–10 mg kg−1 of tranexamic acid every 6 h. Tranexamic acid can also be used for haemostatic management of intraoral bleeding in patients with congenital PAI-1 deficiency, but is less effective when compared with use in patients with congenital α2-PI deficiency. Continuous infusion of 1.5 mg kg−1 h−1 of tranexamic acid is necessary for impacted tooth extraction requiring gingival incision or removal of local bone. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| congenital α2-plasmin inhibitor deficiency Yoshioka, A. verfasserin aut Imai, Y. verfasserin aut Takahashi, Y. oth Minowa, H. oth Kirita, T. oth In Haemophilia Oxford [u.a.] : Wiley-Blackwell, 1995 10(2004), 5, Seite 0 Online-Ressource (DE-627)NLEJ243925867 (DE-600)2006344-1 1365-2516 nnns volume:10 year:2004 number:5 pages:0 http://dx.doi.org/10.1111/j.1365-2516.2004.00914.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 10 2004 5 0 |
| spelling |
10.1111/j.1365-2516.2004.00914.x doi (DE-627)NLEJ242800688 DE-627 ger DE-627 rakwb Morimoto, Y. verfasserin aut Haemostatic management of intraoral bleeding in patients with congenital deficiency of α2-plasmin inhibitor or plasminogen activator inhibitor-1 Oxford, UK Blackwell Science Ltd 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary. Haemostatic management of intraoral bleeding was investigated in patients with congenital α2-plasmin inhibitor (α2-PI) deficiency or congenital plasminogen activator inhibitor- 1 (PAI-1) deficiency. When extracting teeth from patients with congenital α2-PI deficiency, we advocate that 7.5–10 mg kg−1 of tranexamic acid be administered orally every 6 h, starting 3 h before surgery and continuing for about 7 days. For the treatment of continuous bleeding, such as post-extraction bleeding, 20 mg kg−1 of tranexamic acid should be administered intravenously, and after achieving local haemostasis 7.5 mg kg−1 of tranexamic acid should be administered orally every 6 h for several days. In addition, when treating haematoma caused by labial or gingival laceration or buccal or mandibular contusion, haemostasis should be achieved by administering 7.5–10 mg kg−1 of tranexamic acid every 6 h. Tranexamic acid can also be used for haemostatic management of intraoral bleeding in patients with congenital PAI-1 deficiency, but is less effective when compared with use in patients with congenital α2-PI deficiency. Continuous infusion of 1.5 mg kg−1 h−1 of tranexamic acid is necessary for impacted tooth extraction requiring gingival incision or removal of local bone. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| congenital α2-plasmin inhibitor deficiency Yoshioka, A. verfasserin aut Imai, Y. verfasserin aut Takahashi, Y. oth Minowa, H. oth Kirita, T. oth In Haemophilia Oxford [u.a.] : Wiley-Blackwell, 1995 10(2004), 5, Seite 0 Online-Ressource (DE-627)NLEJ243925867 (DE-600)2006344-1 1365-2516 nnns volume:10 year:2004 number:5 pages:0 http://dx.doi.org/10.1111/j.1365-2516.2004.00914.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 10 2004 5 0 |
| allfields_unstemmed |
10.1111/j.1365-2516.2004.00914.x doi (DE-627)NLEJ242800688 DE-627 ger DE-627 rakwb Morimoto, Y. verfasserin aut Haemostatic management of intraoral bleeding in patients with congenital deficiency of α2-plasmin inhibitor or plasminogen activator inhibitor-1 Oxford, UK Blackwell Science Ltd 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary. Haemostatic management of intraoral bleeding was investigated in patients with congenital α2-plasmin inhibitor (α2-PI) deficiency or congenital plasminogen activator inhibitor- 1 (PAI-1) deficiency. When extracting teeth from patients with congenital α2-PI deficiency, we advocate that 7.5–10 mg kg−1 of tranexamic acid be administered orally every 6 h, starting 3 h before surgery and continuing for about 7 days. For the treatment of continuous bleeding, such as post-extraction bleeding, 20 mg kg−1 of tranexamic acid should be administered intravenously, and after achieving local haemostasis 7.5 mg kg−1 of tranexamic acid should be administered orally every 6 h for several days. In addition, when treating haematoma caused by labial or gingival laceration or buccal or mandibular contusion, haemostasis should be achieved by administering 7.5–10 mg kg−1 of tranexamic acid every 6 h. Tranexamic acid can also be used for haemostatic management of intraoral bleeding in patients with congenital PAI-1 deficiency, but is less effective when compared with use in patients with congenital α2-PI deficiency. Continuous infusion of 1.5 mg kg−1 h−1 of tranexamic acid is necessary for impacted tooth extraction requiring gingival incision or removal of local bone. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| congenital α2-plasmin inhibitor deficiency Yoshioka, A. verfasserin aut Imai, Y. verfasserin aut Takahashi, Y. oth Minowa, H. oth Kirita, T. oth In Haemophilia Oxford [u.a.] : Wiley-Blackwell, 1995 10(2004), 5, Seite 0 Online-Ressource (DE-627)NLEJ243925867 (DE-600)2006344-1 1365-2516 nnns volume:10 year:2004 number:5 pages:0 http://dx.doi.org/10.1111/j.1365-2516.2004.00914.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 10 2004 5 0 |
| allfieldsGer |
10.1111/j.1365-2516.2004.00914.x doi (DE-627)NLEJ242800688 DE-627 ger DE-627 rakwb Morimoto, Y. verfasserin aut Haemostatic management of intraoral bleeding in patients with congenital deficiency of α2-plasmin inhibitor or plasminogen activator inhibitor-1 Oxford, UK Blackwell Science Ltd 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary. Haemostatic management of intraoral bleeding was investigated in patients with congenital α2-plasmin inhibitor (α2-PI) deficiency or congenital plasminogen activator inhibitor- 1 (PAI-1) deficiency. When extracting teeth from patients with congenital α2-PI deficiency, we advocate that 7.5–10 mg kg−1 of tranexamic acid be administered orally every 6 h, starting 3 h before surgery and continuing for about 7 days. For the treatment of continuous bleeding, such as post-extraction bleeding, 20 mg kg−1 of tranexamic acid should be administered intravenously, and after achieving local haemostasis 7.5 mg kg−1 of tranexamic acid should be administered orally every 6 h for several days. In addition, when treating haematoma caused by labial or gingival laceration or buccal or mandibular contusion, haemostasis should be achieved by administering 7.5–10 mg kg−1 of tranexamic acid every 6 h. Tranexamic acid can also be used for haemostatic management of intraoral bleeding in patients with congenital PAI-1 deficiency, but is less effective when compared with use in patients with congenital α2-PI deficiency. Continuous infusion of 1.5 mg kg−1 h−1 of tranexamic acid is necessary for impacted tooth extraction requiring gingival incision or removal of local bone. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| congenital α2-plasmin inhibitor deficiency Yoshioka, A. verfasserin aut Imai, Y. verfasserin aut Takahashi, Y. oth Minowa, H. oth Kirita, T. oth In Haemophilia Oxford [u.a.] : Wiley-Blackwell, 1995 10(2004), 5, Seite 0 Online-Ressource (DE-627)NLEJ243925867 (DE-600)2006344-1 1365-2516 nnns volume:10 year:2004 number:5 pages:0 http://dx.doi.org/10.1111/j.1365-2516.2004.00914.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 10 2004 5 0 |
| allfieldsSound |
10.1111/j.1365-2516.2004.00914.x doi (DE-627)NLEJ242800688 DE-627 ger DE-627 rakwb Morimoto, Y. verfasserin aut Haemostatic management of intraoral bleeding in patients with congenital deficiency of α2-plasmin inhibitor or plasminogen activator inhibitor-1 Oxford, UK Blackwell Science Ltd 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary. Haemostatic management of intraoral bleeding was investigated in patients with congenital α2-plasmin inhibitor (α2-PI) deficiency or congenital plasminogen activator inhibitor- 1 (PAI-1) deficiency. When extracting teeth from patients with congenital α2-PI deficiency, we advocate that 7.5–10 mg kg−1 of tranexamic acid be administered orally every 6 h, starting 3 h before surgery and continuing for about 7 days. For the treatment of continuous bleeding, such as post-extraction bleeding, 20 mg kg−1 of tranexamic acid should be administered intravenously, and after achieving local haemostasis 7.5 mg kg−1 of tranexamic acid should be administered orally every 6 h for several days. In addition, when treating haematoma caused by labial or gingival laceration or buccal or mandibular contusion, haemostasis should be achieved by administering 7.5–10 mg kg−1 of tranexamic acid every 6 h. Tranexamic acid can also be used for haemostatic management of intraoral bleeding in patients with congenital PAI-1 deficiency, but is less effective when compared with use in patients with congenital α2-PI deficiency. Continuous infusion of 1.5 mg kg−1 h−1 of tranexamic acid is necessary for impacted tooth extraction requiring gingival incision or removal of local bone. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| congenital α2-plasmin inhibitor deficiency Yoshioka, A. verfasserin aut Imai, Y. verfasserin aut Takahashi, Y. oth Minowa, H. oth Kirita, T. oth In Haemophilia Oxford [u.a.] : Wiley-Blackwell, 1995 10(2004), 5, Seite 0 Online-Ressource (DE-627)NLEJ243925867 (DE-600)2006344-1 1365-2516 nnns volume:10 year:2004 number:5 pages:0 http://dx.doi.org/10.1111/j.1365-2516.2004.00914.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 10 2004 5 0 |
| source |
In Haemophilia 10(2004), 5, Seite 0 volume:10 year:2004 number:5 pages:0 |
| sourceStr |
In Haemophilia 10(2004), 5, Seite 0 volume:10 year:2004 number:5 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
congenital α2-plasmin inhibitor deficiency |
| isfreeaccess_bool |
false |
| container_title |
Haemophilia |
| authorswithroles_txt_mv |
Morimoto, Y. @@aut@@ Yoshioka, A. @@aut@@ Imai, Y. @@aut@@ Takahashi, Y. @@oth@@ Minowa, H. @@oth@@ Kirita, T. @@oth@@ |
| publishDateDaySort_date |
2004-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243925867 |
| id |
NLEJ242800688 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242800688</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210707164245.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2004 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1365-2516.2004.00914.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242800688</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Morimoto, Y.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Haemostatic management of intraoral bleeding in patients with congenital deficiency of α2-plasmin inhibitor or plasminogen activator inhibitor-1</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Science Ltd</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary. Haemostatic management of intraoral bleeding was investigated in patients with congenital α2-plasmin inhibitor (α2-PI) deficiency or congenital plasminogen activator inhibitor- 1 (PAI-1) deficiency. When extracting teeth from patients with congenital α2-PI deficiency, we advocate that 7.5–10 mg kg−1 of tranexamic acid be administered orally every 6 h, starting 3 h before surgery and continuing for about 7 days. For the treatment of continuous bleeding, such as post-extraction bleeding, 20 mg kg−1 of tranexamic acid should be administered intravenously, and after achieving local haemostasis 7.5 mg kg−1 of tranexamic acid should be administered orally every 6 h for several days. In addition, when treating haematoma caused by labial or gingival laceration or buccal or mandibular contusion, haemostasis should be achieved by administering 7.5–10 mg kg−1 of tranexamic acid every 6 h. Tranexamic acid can also be used for haemostatic management of intraoral bleeding in patients with congenital PAI-1 deficiency, but is less effective when compared with use in patients with congenital α2-PI deficiency. Continuous infusion of 1.5 mg kg−1 h−1 of tranexamic acid is necessary for impacted tooth extraction requiring gingival incision or removal of local bone.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2004</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2004||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">congenital α2-plasmin inhibitor deficiency</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yoshioka, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Imai, Y.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takahashi, Y.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Minowa, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kirita, T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Haemophilia</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1995</subfield><subfield code="g">10(2004), 5, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243925867</subfield><subfield code="w">(DE-600)2006344-1</subfield><subfield code="x">1365-2516</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2004</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1365-2516.2004.00914.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2004</subfield><subfield code="e">5</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
Morimoto, Y. |
| spellingShingle |
Morimoto, Y. misc congenital α2-plasmin inhibitor deficiency Haemostatic management of intraoral bleeding in patients with congenital deficiency of α2-plasmin inhibitor or plasminogen activator inhibitor-1 |
| authorStr |
Morimoto, Y. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243925867 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
NL |
| publishPlace |
Oxford, UK |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1365-2516 |
| topic_title |
Haemostatic management of intraoral bleeding in patients with congenital deficiency of α2-plasmin inhibitor or plasminogen activator inhibitor-1 congenital α2-plasmin inhibitor deficiency |
| publisher |
Blackwell Science Ltd |
| publisherStr |
Blackwell Science Ltd |
| topic |
misc congenital α2-plasmin inhibitor deficiency |
| topic_unstemmed |
misc congenital α2-plasmin inhibitor deficiency |
| topic_browse |
misc congenital α2-plasmin inhibitor deficiency |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
y t yt h m hm t k tk |
| hierarchy_parent_title |
Haemophilia |
| hierarchy_parent_id |
NLEJ243925867 |
| hierarchy_top_title |
Haemophilia |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243925867 (DE-600)2006344-1 |
| title |
Haemostatic management of intraoral bleeding in patients with congenital deficiency of α2-plasmin inhibitor or plasminogen activator inhibitor-1 |
| ctrlnum |
(DE-627)NLEJ242800688 |
| title_full |
Haemostatic management of intraoral bleeding in patients with congenital deficiency of α2-plasmin inhibitor or plasminogen activator inhibitor-1 |
| author_sort |
Morimoto, Y. |
| journal |
Haemophilia |
| journalStr |
Haemophilia |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2004 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Morimoto, Y. Yoshioka, A. Imai, Y. |
| container_volume |
10 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
Morimoto, Y. |
| doi_str_mv |
10.1111/j.1365-2516.2004.00914.x |
| author2-role |
verfasserin |
| title_sort |
haemostatic management of intraoral bleeding in patients with congenital deficiency of α2-plasmin inhibitor or plasminogen activator inhibitor-1 |
| title_auth |
Haemostatic management of intraoral bleeding in patients with congenital deficiency of α2-plasmin inhibitor or plasminogen activator inhibitor-1 |
| abstract |
Summary. Haemostatic management of intraoral bleeding was investigated in patients with congenital α2-plasmin inhibitor (α2-PI) deficiency or congenital plasminogen activator inhibitor- 1 (PAI-1) deficiency. When extracting teeth from patients with congenital α2-PI deficiency, we advocate that 7.5–10 mg kg−1 of tranexamic acid be administered orally every 6 h, starting 3 h before surgery and continuing for about 7 days. For the treatment of continuous bleeding, such as post-extraction bleeding, 20 mg kg−1 of tranexamic acid should be administered intravenously, and after achieving local haemostasis 7.5 mg kg−1 of tranexamic acid should be administered orally every 6 h for several days. In addition, when treating haematoma caused by labial or gingival laceration or buccal or mandibular contusion, haemostasis should be achieved by administering 7.5–10 mg kg−1 of tranexamic acid every 6 h. Tranexamic acid can also be used for haemostatic management of intraoral bleeding in patients with congenital PAI-1 deficiency, but is less effective when compared with use in patients with congenital α2-PI deficiency. Continuous infusion of 1.5 mg kg−1 h−1 of tranexamic acid is necessary for impacted tooth extraction requiring gingival incision or removal of local bone. |
| abstractGer |
Summary. Haemostatic management of intraoral bleeding was investigated in patients with congenital α2-plasmin inhibitor (α2-PI) deficiency or congenital plasminogen activator inhibitor- 1 (PAI-1) deficiency. When extracting teeth from patients with congenital α2-PI deficiency, we advocate that 7.5–10 mg kg−1 of tranexamic acid be administered orally every 6 h, starting 3 h before surgery and continuing for about 7 days. For the treatment of continuous bleeding, such as post-extraction bleeding, 20 mg kg−1 of tranexamic acid should be administered intravenously, and after achieving local haemostasis 7.5 mg kg−1 of tranexamic acid should be administered orally every 6 h for several days. In addition, when treating haematoma caused by labial or gingival laceration or buccal or mandibular contusion, haemostasis should be achieved by administering 7.5–10 mg kg−1 of tranexamic acid every 6 h. Tranexamic acid can also be used for haemostatic management of intraoral bleeding in patients with congenital PAI-1 deficiency, but is less effective when compared with use in patients with congenital α2-PI deficiency. Continuous infusion of 1.5 mg kg−1 h−1 of tranexamic acid is necessary for impacted tooth extraction requiring gingival incision or removal of local bone. |
| abstract_unstemmed |
Summary. Haemostatic management of intraoral bleeding was investigated in patients with congenital α2-plasmin inhibitor (α2-PI) deficiency or congenital plasminogen activator inhibitor- 1 (PAI-1) deficiency. When extracting teeth from patients with congenital α2-PI deficiency, we advocate that 7.5–10 mg kg−1 of tranexamic acid be administered orally every 6 h, starting 3 h before surgery and continuing for about 7 days. For the treatment of continuous bleeding, such as post-extraction bleeding, 20 mg kg−1 of tranexamic acid should be administered intravenously, and after achieving local haemostasis 7.5 mg kg−1 of tranexamic acid should be administered orally every 6 h for several days. In addition, when treating haematoma caused by labial or gingival laceration or buccal or mandibular contusion, haemostasis should be achieved by administering 7.5–10 mg kg−1 of tranexamic acid every 6 h. Tranexamic acid can also be used for haemostatic management of intraoral bleeding in patients with congenital PAI-1 deficiency, but is less effective when compared with use in patients with congenital α2-PI deficiency. Continuous infusion of 1.5 mg kg−1 h−1 of tranexamic acid is necessary for impacted tooth extraction requiring gingival incision or removal of local bone. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
5 |
| title_short |
Haemostatic management of intraoral bleeding in patients with congenital deficiency of α2-plasmin inhibitor or plasminogen activator inhibitor-1 |
| url |
http://dx.doi.org/10.1111/j.1365-2516.2004.00914.x |
| remote_bool |
true |
| author2 |
Yoshioka, A. Imai, Y. Takahashi, Y. Minowa, H. Kirita, T. |
| author2Str |
Yoshioka, A. Imai, Y. Takahashi, Y. Minowa, H. Kirita, T. |
| ppnlink |
NLEJ243925867 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1111/j.1365-2516.2004.00914.x |
| up_date |
2024-07-06T03:14:29.132Z |
| _version_ |
1803797836996804608 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242800688</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210707164245.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2004 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1365-2516.2004.00914.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242800688</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Morimoto, Y.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Haemostatic management of intraoral bleeding in patients with congenital deficiency of α2-plasmin inhibitor or plasminogen activator inhibitor-1</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Science Ltd</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary. Haemostatic management of intraoral bleeding was investigated in patients with congenital α2-plasmin inhibitor (α2-PI) deficiency or congenital plasminogen activator inhibitor- 1 (PAI-1) deficiency. When extracting teeth from patients with congenital α2-PI deficiency, we advocate that 7.5–10 mg kg−1 of tranexamic acid be administered orally every 6 h, starting 3 h before surgery and continuing for about 7 days. For the treatment of continuous bleeding, such as post-extraction bleeding, 20 mg kg−1 of tranexamic acid should be administered intravenously, and after achieving local haemostasis 7.5 mg kg−1 of tranexamic acid should be administered orally every 6 h for several days. In addition, when treating haematoma caused by labial or gingival laceration or buccal or mandibular contusion, haemostasis should be achieved by administering 7.5–10 mg kg−1 of tranexamic acid every 6 h. Tranexamic acid can also be used for haemostatic management of intraoral bleeding in patients with congenital PAI-1 deficiency, but is less effective when compared with use in patients with congenital α2-PI deficiency. Continuous infusion of 1.5 mg kg−1 h−1 of tranexamic acid is necessary for impacted tooth extraction requiring gingival incision or removal of local bone.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2004</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2004||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">congenital α2-plasmin inhibitor deficiency</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yoshioka, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Imai, Y.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takahashi, Y.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Minowa, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kirita, T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Haemophilia</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1995</subfield><subfield code="g">10(2004), 5, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243925867</subfield><subfield code="w">(DE-600)2006344-1</subfield><subfield code="x">1365-2516</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2004</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1365-2516.2004.00914.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2004</subfield><subfield code="e">5</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.3985195 |